BACKGROUND Aprotinin has been used to reduce blood loss and blood product transfusions in patients at high risk of major blood loss during cardiac surgery. Approval by the European Medicines Agency (EMA) for its current indication is limited to patients at high risk of major blood loss undergoing isolated coronary artery bypass graft surgery (iCABG). OBJECTIVE To report current real-world data on the use and certain endpoints related to the safety of aprotinin in adult patients. DESIGN The Nordic aprotinin patient registry (NAPaR) received data from 83 European centres in a noninterventional, postauthorisation safety study (PASS) performed at the request of the EMA. SETTING Cardiac surgical centres committed to enrolling patients in the NAP...
AbstractBackground: Aprotinin reduces blood loss after cardiopulmonary bypass. Although there can be...
Abstract Background An estimated up to 7% of high-risk cardiac surgery patients return to the operat...
PURPOSE: Medical decisions are often made based on personal experience or on limited clinical trial ...
Study Objectives. To determine if aprotinin is safe and effective in patients at low risk for requir...
ObjectiveThe antifibrinolytic drug aprotinin has been the most widely used agent to reduce bleeding ...
Aprotinin, a serine protease inhibitor, has recently been shown to reduce blood loss in cardiac surg...
Background: There is still uncertainty about the safety of aprotinin for coronary artery bypass graf...
BACKGROUND: There is still uncertainty about the safety of aprotinin for coronary artery bypass graf...
ObjectivesAprotinin is a drug used to reduce bleeding in patients undergoing cardiothoracic surgery ...
OBJECTIVE: Despite proven blood transfusion benefits, aprotinin may be underused in coronary artery ...
ObjectiveUse of aprotinin has been suspended in cardiac surgery since recent studies reported its ri...
AbstractObjectiveDespite proven blood transfusion benefits, aprotinin may be underused in coronary a...
To assess the impact of systematic use of aprotinin, 115 consecutive adults undergoing cardiac surge...
Background. Aprotinin, a non-specific serine protease inhibitor, has been used for two decades to re...
Background: Because of recent concerns about the safety of aprotinin, we updated our 2007 Cochrane r...
AbstractBackground: Aprotinin reduces blood loss after cardiopulmonary bypass. Although there can be...
Abstract Background An estimated up to 7% of high-risk cardiac surgery patients return to the operat...
PURPOSE: Medical decisions are often made based on personal experience or on limited clinical trial ...
Study Objectives. To determine if aprotinin is safe and effective in patients at low risk for requir...
ObjectiveThe antifibrinolytic drug aprotinin has been the most widely used agent to reduce bleeding ...
Aprotinin, a serine protease inhibitor, has recently been shown to reduce blood loss in cardiac surg...
Background: There is still uncertainty about the safety of aprotinin for coronary artery bypass graf...
BACKGROUND: There is still uncertainty about the safety of aprotinin for coronary artery bypass graf...
ObjectivesAprotinin is a drug used to reduce bleeding in patients undergoing cardiothoracic surgery ...
OBJECTIVE: Despite proven blood transfusion benefits, aprotinin may be underused in coronary artery ...
ObjectiveUse of aprotinin has been suspended in cardiac surgery since recent studies reported its ri...
AbstractObjectiveDespite proven blood transfusion benefits, aprotinin may be underused in coronary a...
To assess the impact of systematic use of aprotinin, 115 consecutive adults undergoing cardiac surge...
Background. Aprotinin, a non-specific serine protease inhibitor, has been used for two decades to re...
Background: Because of recent concerns about the safety of aprotinin, we updated our 2007 Cochrane r...
AbstractBackground: Aprotinin reduces blood loss after cardiopulmonary bypass. Although there can be...
Abstract Background An estimated up to 7% of high-risk cardiac surgery patients return to the operat...
PURPOSE: Medical decisions are often made based on personal experience or on limited clinical trial ...